Inclusion Criteria:  Provision of signed and dated consent form Stated willingness to comply with all study procedures and availability for the duration of the study Male or female, aged between 18 - 65 years old WOMAC ≥ 50 Kellgren-Lawrence Grade 2 or higher on Hip X-Rays Body Mass Index < 35 kg/m2 Unilateral or Bilateral Hip Osteoarthritis Prior physical therapy treatment for 6 weeks in the last 6 months Agreement to adhere to Lifestyle Considerations (see section 5.3) At least 60 cc of BMAC acquired during aspiration/concentration process Discontinuation of pain/anti-inflammatory medications 2 week prior to baseline measurements Patients with cancer in remission for at least 5 years Total Nucleated cell count (TNC) ≥ 40 x 106 cells/mL Platelet Concentration ≥ 600 x 106 cells/mL Endotoxin < 0.5 EU/device output Viability ≥ 90% Negative gram stain result  Exclusion Criteria:  Prior corticosteroid injection to the hip History of hip replacement(s) Noncompliance to prevent screening tests for cancer indicated by age Active autoimmune disease Current use of oral corticosteroid Inability to be weaned of oral anti-inflammatory medications History of Diabetes or HbA1c > 6.5% Uncontrolled Thyroid Dysfunction: 0.450 uIU/mL ≥ TSH levels ≥ 4.500 uIU/mL Vitamin D Level < 30 ng/ml Anemia (Hgb < 12 g/dL for Women; Hgb < 13 g/dL for men) eGFR < 60 mL/min/1.73 m^2 Thrombocytopenia with platelet count less than 150,000 x 109 L Patients with coagulopathies based on known clotting disorder Patients currently on anti-coagulation therapies Patients who report any active infection(s) including cellulitis, TB, HIV, COVID, Hepatitis B and C Moving over the next year Inability to consent to the research study Inability to complete forms electronically Subjects in any other clinical trials History of allergic reaction to lidocaine